BioPharma Dive September 16, 2024
Legislation that passed the House of Representatives passed the Biosecure Act last week would force U.S. biotechs to cut ties with five Chinese contract partners.
Some of the most widely used drug contractors are based in China. But the U.S. biopharmaceutical industry may eventually be pushed to cut ties with those partners if the Biosecure Act, which passed in the House of Representatives last week, becomes law.
The act would effectively prohibit U.S. companies from doing business with five Chinese firms, including WuXi AppTec, Complete Genomics and MGI Tech. In the House’s version, companies with existing contracts are given eight years to sever ties. The bill also allows Congress to add more companies to its list as it weighs perceived...
Today's Sponsors
Today's Sponsor